Figure 5.

G3 and 4D5 CAR-T cells exhibit better tumor infiltration. Tumors and spleens were made into single-cell suspensions with a 70 μm strainer and were stained with the appropriate fluorescent antibodies. (A and B) Representative plots of CD45⁺CD3⁺ and CD45⁺CD8⁺ cells isolated from tumor tissue were stained using PacificBlue-conjugated anti-human CD45 and FITC-conjugated anti-human CD3 or CD8, respectively. (C and D) Summarized data from CD45⁺CD3⁺ and CD45⁺CD8⁺ cells isolated from tumor, blood, and spleen is displayed herein. (E) Quantiative polymerase chain reaction (qPCR) data detecting CAR⁺ T cells in the tumor. Total mRNA was extracted from tumor samples and was used for qPCR in triplicate, and percentages of CAR⁺ T cells subsequently were obtained from a standard curve. For all graphs, cells were harvested 7 days after CAR-T cell injection (n = 3, mean ± SEM; NS, not significant; *p < 0.05.